The following is a sample from a larger document.
This section is for: Risks and Open Questions
The section is from a Focused Issue Brief on: Assessing Scientific Causation Claims in PFAS Exposure Litigation
The primary research jurisdiction is: United States of America
[Back]
Risks and Open Questions
The PFAS litigation landscape sits on unstable ground. What attorneys consider established science today may face serious challenge within the litigation timeline of active cases. What courts accept as reliable methodology now may be rejected after methodological scrutiny intensifies. What regulatory agencies treat as settled policy may reverse as political pressure mounts and new data emerges.
Regulatory change is likely. EPA’s current PFAS regulatory framework represents an interim position, not a settled one. The agency has committed to Maximum Contaminant Level rulings for additional PFAS compounds beyond PFOA and PFOS by 2026, but the scientific basis for those levels remains contested within EPA itself. Public records and stakeholder commentary reflect disagreement about acceptable exposure thresholds, with differing views on appropriate safety margins and economic considerations.
This internal tension creates litigation risk in two directions. Courts may discover that EPA’s public positions were not supported by its own scientific staff, undermining the regulatory presumption that often supports plaintiff cases. Alternatively, more restrictive standards may emerge that make current exposure levels appear negligent in retrospect, strengthening future claims while complicating the defense of past conduct. Neither outcome follows predictably from current agency statements.
EPA’s rule-making process for additional PFAS compounds will generate thousands of pages of scientific review, public comment, and agency response that did not exist when current cases were filed. Expert witnesses who testify confidently about “established” safe exposure levels may find themselves contradicted by EPA’s own final determinations before cases reach trial. Courts have little guidance on how to handle situations where federal regulatory standards shift materially during pending litigation.
The epidemiological evidence base remains fragile. Most human studies rely on biomonitoring data that measures PFAS blood levels at a single point in time, then attempts to correlate those measurements with health outcomes. This approach assumes that current blood levels reflect historical exposure patterns, but PFAS elimination rates from the human body vary dramatically between compounds and individuals.
PFOA has an elimination half-life of approximately 3.8 years in humans, meaning that blood levels measured today reflect exposures from multiple years in the past. PFOS has an even longer half-life at roughly 5.4 years. For individuals with mixed exposure to multiple PFAS compounds over decades, current biomonitoring provides only an approximation of cumulative exposure. As defense experts become more sophisticated in challenging biomonitoring assumptions, the evidentiary foundation for many exposure-outcome correlations may weaken.
Early PFAS epidemiological studies used general population samples as controls, assuming that PFAS exposure in those groups was minimal or absent. As ubiquitous environmental contamination becomes better documented, this assumption breaks down. Recent biomonitoring studies continue to report detectable PFAS levels in the large majority of tested individuals across multiple geographic regions.
When everyone has measurable exposure, traditional case-control study designs lose statistical power.
Researchers are developing new analytical approaches to address this problem, but those methodologies are not yet standardized. Courts will face competing expert testimony about which analytical framework provides the most reliable basis for causal inference, with no clear scientific consensus to guide judicial decisions. The transition period, likely extending through 2027, creates particular vulnerability for cases that reach trial during the methodological shift.
Mechanistic understanding may fragment rather than consolidate. Current mechanistic theories about how PFAS compounds cause human disease rely heavily on studies conducted in laboratory animals and in vitro cell culture systems. These studies consistently show that PFAS exposure disrupts multiple biological pathways, including lipid metabolism, immune system function, and hormone signaling. The mechanistic evidence appears robust until examined for human relevance.
Animal studies typically use PFAS doses higher than human environmental exposures. The assumption that effects observed at high experimental doses will occur at lower environmental doses depends on the shape of the dose-response curve in the low-dose region, which cannot be directly measured in human studies. Linear extrapolation from high-dose effects may overestimate risk, while threshold models may underestimate it.
Recent research suggests that PFAS effects may be non-monotonic, meaning that the biological response does not increase steadily with dose. Some studies indicate that certain PFAS effects are stronger at moderate doses than at very high doses, potentially due to receptor saturation or compensatory biological responses. Non-monotonic dose-response relationships complicate regulatory standard-setting and make expert predictions about health effects at specific exposure levels far less reliable than they appear.
Human PFAS exposure involves simultaneous contact with hundreds of related compounds, not just the handful that have been extensively studied. Recent advances in mass spectrometry allow detection of previously unknown PFAS compounds in environmental and human samples. Some of these compounds show biological activity profiles that differ substantially from well-studied PFAS like PFOA and PFOS.
Whether mixture effects are additive, synergistic, or antagonistic remains unknown for most PFAS combinations found in human populations. Toxicological studies of individual compounds may not predict the health effects of realistic multi-compound exposures. As the analytical capacity to identify and measure PFAS mixtures improves, current risk assessments based on single-compound studies may prove inadequate. This could strengthen plaintiff arguments about underestimated health risks while simultaneously undermining the specificity of causation claims.
Federal courts show increased willingness to exclude expert testimony that lacks adequate scientific foundation, particularly in toxic tort cases. The Supreme Court’s emphasis on reliability in Daubert has filtered down to more aggressive gatekeeping by trial judges, with meaningful consequences for PFAS litigation.
PFAS health effects span toxicology, epidemiology, environmental chemistry, and clinical medicine. Few experts possess deep competence across all relevant disciplines, but effective PFAS testimony requires integration of knowledge from multiple fields. Courts increasingly reject expert testimony that ventures substantially outside the witness’s primary area of expertise, even when the opinion sounds authoritative.
Expert witnesses who built reputations testifying about other environmental contaminants may find that PFAS-specific knowledge is now required. The unique environmental persistence, bioaccumulation patterns, and toxicological profiles of PFAS compounds distinguish them from previously litigated substances like asbestos or lead. Generic environmental health expertise no longer suffices for detailed testimony about PFAS exposure pathways or health effects.
Courts expect expert opinions to be supported by peer-reviewed research, but PFAS science continues developing rapidly. Expert witnesses who testify based on preliminary data or conference presentations face heightened scrutiny if those findings are later contradicted by peer-reviewed studies. The publication lag in scientific journals means that expert testimony may rely on information that is months or years behind the current state of knowledge.
Early PFAS cases often involved plaintiffs with clear exposure sources: contaminated drinking water, occupational contact, or proximity to known contamination sites. As environmental PFAS levels increase throughout the population, establishing that specific exposure sources caused particular health effects becomes more difficult.
Studies from the early 2000s showed that most Americans had detectable but relatively low PFAS blood levels. More recent biomonitoring indicates shifting exposure patterns in some population groups, including children, depending on compound type and exposure source.
Higher background exposures make it harder to demonstrate that specific defendants contributed meaningfully to plaintiff health risks.
PFAS compounds are used in waterproof clothing, non-stick cookware, food packaging, carpeting, and hundreds of other consumer products. Individual exposure histories may involve dozens of potential sources that are difficult to quantify retrospectively. Defense attorneys increasingly argue that consumer product exposures dwarf environmental contamination, making specific site attribution speculative.
Many health effects allegedly linked to PFAS exposure develop over decades, during which plaintiffs may have encountered multiple exposure sources. Proving that contamination from a specific facility during a particular time period caused health effects that manifested years later becomes more challenging when background exposure levels have increased substantially during the intervening period.
PFAS analytical methods continue improving rapidly, with new techniques detecting compounds that were previously unmeasurable. Advanced analytical techniques can detect numerous additional fluorinated compounds in environmental samples, many of which have not been studied for health effects. As analytical capacity improves, the fraction of total PFAS contamination represented by well-characterized compounds decreases.
Current PFAS litigation focuses primarily on compounds that can be reliably measured: PFOA, PFOS, PFNA, and a handful of others.
This analytical evolution creates legal complications for both sides. Plaintiff attorneys may argue that unmeasured PFAS compounds represent additional health risks not accounted for in current assessments. Defense attorneys may contend that health effects attributed to measured compounds are actually caused by unmeasured ones, breaking the causal chain. Neither argument can be definitively resolved without extensive research on previously unknown compounds.
Historical exposure reconstruction becomes less reliable as analytical knowledge improves. Many PFAS cases depend on modeling historical contamination levels based on current environmental measurements and assumptions about past industrial practices. These models assume that measured compounds represent a consistent fraction of total PFAS contamination over time. If the composition of PFAS mixtures has changed substantially due to evolving industrial uses, historical exposure estimates may be systematically biased.
Federal PFAS regulation continues expanding, with uncertain implications for state tort claims. EPA’s developing regulatory framework may eventually preempt state law claims entirely, partially, or not at all, depending on how courts interpret the relationship between federal environmental standards and state tort liability.
If EPA establishes comprehensive PFAS regulations while cases are pending, courts will need to determine whether those regulations preempt claims based on conduct that occurred before the regulations took effect. The retroactivity question has no clear answer in existing environmental preemption doctrine.
Several states have enacted PFAS-specific legislation that is more restrictive than current federal standards. Whether state regulations strengthen plaintiff cases by establishing stricter standards of care, or create preemption defenses for defendants who complied with applicable federal rules, depends on jurisdiction-specific legal doctrines that have not been definitively resolved.
The general causation requirement in toxic tort cases demands reliable scientific evidence that a substance is capable of causing the type of harm alleged. PFAS science has been cited in support of general causation claims for several health endpoints, though the strength of that support depends on how courts evaluate epidemiological evidence with acknowledged limitations.
The replication crisis in environmental health research affects PFAS studies along with other fields. Some influential PFAS health studies have not yet been independently replicated, and certain findings have been questioned or refined by subsequent research. As courts become more sophisticated about evaluating scientific reliability, studies that appeared decisive when published may face successful challenge at trial.
Regulatory agencies accept epidemiological evidence as sufficient for policy-making even when mechanistic understanding is incomplete. Courts applying evidentiary standards for individual liability determinations may demand higher levels of scientific certainty than regulatory decision-making requires. This gap between regulatory sufficiency and legal proof may widen as PFAS litigation matures.
European regulatory agencies have reached different conclusions about PFAS health risks than their U.S. counterparts in several cases, based on analysis of the same underlying studies. As international scientific dialogue continues, U.S. courts may encounter expert testimony arguing that American regulatory positions are outliers in the global scientific community.
You must track these shifting dynamics and evaluate their impact on specific cases. What appears settled today may be vigorously contested tomorrow. What seems like strong regulatory support may evaporate as agency positions evolve. What looks like reliable scientific consensus may fragment under methodological scrutiny. Professional judgment must account for this instability rather than assume that current conditions will persist through trial.
[Back]